

DAFTAR PUSTAKA

1. McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. *The Lancet*. 2017;389(10086):2328–37.
2. Kanis JA, Cooper C, Rizzoli R, Reginster JY. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. *Osteoporosis International*. 2019;30(1):3–44.
3. Riskesdas K. Hasil Utama Riset Kesehatan Dasar (RISKESDAS). *J Phys A Math Theor*. 2020;44(8):1–200.
4. Phuan-udom R, Lektrakul N, Katchamart W. The association between CTX-1 with disease activity in patients with rheumatoid arthritis. *Clin Rheumatol*. 2018;37(10):2603–10.
5. Tobeiha M, Moghadasian MH, Amin N, Jafarnejad S. RANKL/RANK/OPG Pathway: A Mechanism Involved in Exercise-Induced Bone Remodeling. *Biomed Res Int*. 2020;2020:1–11.
6. Nava-Valdivia CA, Ponce-Guarneros JM, Saldaña-Cruz AM, Corona-Sanchez EG, Ramirez-Villafaña M, Perez-Guerrero EE, et al. Assessment of Serum sRANKL, sRANKL/OPG Ratio, and Other Bone Turnover Markers with the Estimated 10-Year Risk of Major and Hip Osteoporotic Fractures in Rheumatoid Arthritis: A Cross-Sectional Study. *Biomed Res Int*. 2021;2021:1–13.
7. Chauhan K, Jandu JS, Brent LH, Al-Dhahir MA. Rheumatoid Arthritis. [Updated 2023 May 25]. In: StatPearls [Internet]. Treasure Island [FL]: StatPearls Publishing; 2024.
8. Radu AF, Bungau SG. Management of Rheumatoid Arthritis: An Overview. *Cells*. 2021;10(11):2857.
9. Safiri S, Kolahi AA, Hoy D, Smith E, Bettampadi D, Mansournia MA, et al. Global, regional and national burden of rheumatoid arthritis 1990–2017: a systematic analysis of the Global Burden of Disease study 2017. *Ann Rheum Dis*. 2019;78(11):1463–71.
10. Almutairi K, Nossent J, Preen D, Keen H, Inderjeeth C. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. *Rheumatol Int*. 2021;41(5):863–77.

11. Myasoedova E, Davis J, Matteson EL, Crowson CS. Is the epidemiology of rheumatoid arthritis changing? Results from a population-based incidence study, 1985–2014. *Ann Rheum Dis*. 2020;79(4):440–4.
12. Taylor-Gjevre R, Nair B, Jin S, Quail J. Geographic variation in incidence and prevalence rates for rheumatoid arthritis in Saskatchewan, Canada 2001–2014. *Canadian Journal of Public Health*. 2018;109(3):427–35.
13. Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. *Nat Rev Dis Primers*. 2018;4(1):18001.
14. Dedmon LE. The genetics of rheumatoid arthritis. *Rheumatology*. 2020;59(10):2661–70.
15. Padyukov L. Genetics of rheumatoid arthritis. *Semin Immunopathol*. 2022;44(1):47–62.
16. Karami J, Aslani S, Tahmasebi MN, Mousavi MJ, Sharafat Vaziri A, Jamshidi A, et al. Epigenetics in rheumatoid arthritis; fibroblast-like synoviocytes as an emerging paradigm in the pathogenesis of the disease. *Immunol Cell Biol*. 2020;98(3):171–86.
17. Nemtsova M V., Zaletaev D V., Bure I V., Mikhaylenko DS, Kuznetsova EB, Alekseeva EA, et al. Epigenetic Changes in the Pathogenesis of Rheumatoid Arthritis. *Front Genet*. 2019;10:570.
18. Novella-Navarro M, Plasencia-Rodríguez C, Nuño L, Balsa A. Risk Factors for Developing Rheumatoid Arthritis in Patients With Undifferentiated Arthritis and Inflammatory Arthralgia. *Frontiers in Medicine (Lausanne)*. 2021;8:668898.
19. Roh S. Smoking as a Preventable Risk Factor for Rheumatoid Arthritis: Rationale for Smoking Cessation Treatment in Patients with Rheumatoid Arthritis. *Journal of Rheumatic Diseases*. 2019;26(1):12–9.
20. Ishikawa Y, Terao C. The Impact of Cigarette Smoking on Risk of Rheumatoid Arthritis: A Narrative Review. *Cells*. 2020;9(2):475.
21. Wrangel O, Graff P, Bryngelsson IL, Fornander L, Wiebert P, Vihlborg P. Silica Dust Exposure Increases Risk for Rheumatoid Arthritis. *J Occup Environ Med*. 2021;63(11):951–5.

22. Tsetseri MN, Silman AJ, Keene DJ, Dakin SG. The role of the microbiome in rheumatoid arthritis: a review. *Rheumatol Adv Pract.* 2023;7(2).
23. Zhao T, Wei Y, Zhu Y, Xie Z, Hai Q, Li Z, et al. Gut microbiota and rheumatoid arthritis: From pathogenesis to novel therapeutic opportunities. *Front Immunol.* 2022;13:1007165.
24. Petrovská N, Prajzlerová K, Vencovský J, Šenolt L, Filková M. The pre-clinical phase of rheumatoid arthritis: From risk factors to prevention of arthritis. *Autoimmun Rev.* 2021;20(5):102797.
25. Nanke Y. The Pathogenesis of Rheumatoid Arthritis Breakthroughs in Molecular Mechanisms 1 and 2. *Int J Mol Sci.* 2023 Jul 4;24(13):11060.
26. Mueller AL, Payandeh Z, Mohammadkhani N, Mubarak SMH, Zakeri A, Alagheband Bahrami A, et al. Recent Advances in Understanding the Pathogenesis of Rheumatoid Arthritis: New Treatment Strategies. *Cells.* 2021;10(11):3017.
27. Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. *Bone Res.* 2018;6(1):15–28.
28. Lin YJ, Anzaghe M, Schülke S. Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis. *Cells.* 2020;9(4):880.
29. Sakthiswary R, Uma Veshaliini R, Chin KY, Das S, Sirasanagandla SR. Pathomechanisms of bone loss in rheumatoid arthritis. *Frontiers in Medicine.* 2022;9:962969.
30. Fardellone P, Salawati E, Le Monnier L, Goëb V. Bone Loss in Patients with Rheumatoid Arthritis: A Review. *J Clin Med.* 2020;9(10):3361.
31. Maeda K, Yoshida K, Nishizawa T, Otani K, Yamashita Y, Okabe H, et al. Inflammation and Bone Metabolism in Rheumatoid Arthritis: Molecular Mechanisms of Joint Destruction and Pharmacological Treatments. *Int J Mol Sci.* 2022;23(5):2871.
32. Kareem R, Botleroo RA, Bhandari R, Ogeyingbo OD, Ahmed R, Gyawali M, et al. The Impact of Rheumatoid Arthritis on Bone Loss. *Cureus.* 2021;13(8):e17519.

33. Aletaha D, Smolen JS. Diagnosis and Management of Rheumatoid Arthritis. *JAMA*. 2018;320(13):1360.
34. Hashimoto A, Suto S, Horie K, Fukuda H, Nogi S, Iwata K, et al. Incidence and Risk Factors for Infections Requiring Hospitalization, Including Pneumocystis Pneumonia, in Japanese Patients with Rheumatoid Arthritis. *Int J Rheumatol*. 2017:1–8.
35. DeMizio DJ, Geraldino-Pardilla LB. Autoimmunity and Inflammation Link to Cardiovascular Disease Risk in Rheumatoid Arthritis. *Rheumatol Ther*. 2020;7(1):19–33.
36. Avramidis GP, Avramidou MP, Papakostas GA. Rheumatoid Arthritis Diagnosis: Deep Learning vs. Humane. *Applied Sciences*. 2021;12(1):10.
37. Hassan R, Faruqui H, Alquraa R, Eissa A, Alshaiki F, Cheikh M. Classification Criteria and Clinical Practice Guidelines for Rheumatic Diseases. In: Almoallim H, Cheikh M, editors. *Skills in Rheumatology*. Singapore: Springer Singapore; 2021. p. 521–66.
38. Seabra Rato M, Oliveira Pinheiro F, Garcia S, Fernandes B, Bernardo A, Gaio R, et al. rheumatoid arthritis assessed with and without bone mineral density - are we treating our patients under bDMARDs? *ARP rheumatology*. 2023;2(1):47–52.
39. Tong J jing, Xu S qian, Zong H xiang, Pan M juan, Teng Y zhu, Xu J hua. Prevalence and risk factors associated with vertebral osteoporotic fractures in patients with rheumatoid arthritis. *Clin Rheumatol*. 2020;39(2):357–64.
40. Adami G, Saag KG. Osteoporosis Pathophysiology, Epidemiology, and Screening in Rheumatoid Arthritis. *Curr Rheumatol Rep*. 2019;21(7):34.
41. Chavda S, Chavda B, Dube R. Rheumatoid arthritis associated with reabsorptive factor in General Clinical Practice. *Cureus*. 2022;14(7):e26518.
42. Kanis JA, Johansson H, Harvey NC, McCloskey E V. A brief history of RA. *Arch Osteoporos*. 2018;13(1):118.
43. McCloskey E V., Harvey NC, Johansson H, Kanis JA. Rheumatoid arthritis related bone loss. *Curr Opin Rheumatol*. 2016;28(4):433–41.
44. Handono K, Putra SB, Sulistyorini S. Korelasi Kadar CRP, TNF- α dan Densitas massa tulang dengan Carboxyterminal Crosslinked Telopeptide of

- Type 1 Collagen di Penderita arthritis reumatoid. *Indones J Clin Pathol Med Lab.* 2012;18(2):72–82
45. Engvall IL, Svensson B, Tengstrand B, Brismar K, Hafström I. Impact of low-dose prednisolone on bone synthesis and resorption in early rheumatoid arthritis: Experiences from a two-year randomized study. *Arthritis Res Ther.* 2018;10(6):1–12.
 46. Li M, Li Y, Deng W, Zhang Z, Deng Z, Hu Y, et al. Chinese Bone Turnover Marker Study: Reference ranges for C-terminal telopeptide of type I collagen and procollagen I N-terminal peptide by age and gender. *PLoS One.* 2019;9(8):5–11.
 47. Vasikaran S, Cooper C, Eastell R, Griesmacher A, Morris HA, et al. International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis. *Clin Chem Lab Med.* 2019; 49: 1271–1274.
 48. Papadaki M, Rintotas V, Violitzi F, Thireou T, Panayotou G, Samiotaki M, et al. New Insights for RANKL as a Proinflammatory Modulator in Modeled Inflammatory Arthritis. *Front Immunol.* 2019;10:97.
 49. Okamoto K, Takayanagi H. Osteoimmunology. In: Thakker R V, Whyte MP, Eisman JA, Igarashi T, editors. *Genetics of Bone Biology and Skeletal Disease.* 2nd ed. Elsevier; 2018. p. 261–82.
 50. Llorente I, García-Castañeda N, Valero C, González-Álvaro I, Castañeda S. Osteoporosis in Rheumatoid Arthritis: Dangerous Liaisons. *Front Med (Lausanne).* 2020;7:601618.
 51. Park JH, Lee NK, Lee SY. Current Understanding of RANK Signaling in Osteoclast Differentiation and Maturation. *Mol Cells.* 2017;40(10):706–13.
 52. Fang Q, Zhou C, Nandakumar KS. Molecular and Cellular Pathways Contributing to Joint Damage in Rheumatoid Arthritis. *Mediators Inflamm.* 2020 Mar 17;2020:1–20.
 53. Balendran T, Lim K, Hamilton JA, Achuthan AA. Targeting transcription factors for therapeutic benefit in rheumatoid arthritis. *Front Immunol.* 2023;14:1196931.

54. Zhou C, You Y, Shen W, Zhu YZ, Peng J, Feng HT, et al. Deficiency of sorting nexin 10 prevents bone erosion in collagen-induced mouse arthritis through promoting NFATc1 degradation. *Ann Rheum Dis*. 2016;75(6):1211–8.
55. Choi HK, Kang HR, Jung E, Kim TE, Lin JJ, Lee SY. Early estrogen-induced gene 1, a novel RANK signaling component, is essential for osteoclastogenesis. *Cell Res*. 2013;23(4):524–36.
56. Jackson JT, Mulazzani E, Nutt SL, Masters SL. The role of PLC γ 2 in immunological disorders, cancer, and neurodegeneration. *Journal of Biological Chemistry*. 2021;297(2):100905.
57. Danks L, Komatsu N, Guerrini MM, Sawa S, Armaka M, Kollias G, et al. RANKL expressed on synovial fibroblasts is primarily responsible for bone erosions during joint inflammation. *Ann Rheum Dis*. 2016;75(6):1187–95.
58. Srivastava RK, Dar HY, Mishra PK. Immunoporosis: Immunology of Osteoporosis—Role of T Cells. *Front Immunol*. 2018;9:657.
59. Raphael I, Nalawade S, Eagar TN, Forsthuber TG. T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. *Cytokine*. 2019;74(1):5–17.
60. Komatsu N, Takayanagi H. Immune-bone interplay in the structural damage in rheumatoid arthritis. *Clin Exp Immunol*. 2018;194(1):1–8.
61. Fang Q, Zhou C, Nandakumar KS. Molecular and Cellular Pathways Contributing to Joint Damage in Rheumatoid Arthritis. *Mediators Inflamm*. 2020;2020:1–20.
62. Osta B, Benedetti G, Miossec P. Classical and Paradoxical Effects of TNF- α on Bone Homeostasis. *Front Immunol*. 2014;5:48.
63. Ma Y, Shi X, Zhao H, Song R, Zou H, Zhu J, et al. Potential mechanisms of osteoprotegerin-induced damage to osteoclast adhesion structures via P2X7R-mediated MAPK signaling. *Int J Mol Med*. 2022;49(5):59.
64. Yasuda H. Discovery of the RANKL/RANK/OPG system. *J Bone Miner Metab*. 2021;39(1):2–11.
65. Fu YX, Gu JH, Zhang YR, Tong XS, Zhao HY, Yuan Y, et al. Osteoprotegerin influences the bone resorption activity of osteoclasts. *Int J Mol Med*. 2013;31(6):1411–7.

66. Jura-Póltorak A, Szeremeta A, Olczyk K, Zoń-Giebel A, Komosińska-Vassev K. Bone Metabolism and RANKL/OPG Ratio in Rheumatoid rthritis women treated with TNF- α inhibitors. *J Clin Med*. 2021;10(13):2905.
67. Remuzgo-Martínez S, Genre F, López-Mejías R, Ubilla B, Mijares V, Pina T, et al. Expression of osteoprotegerin and its ligands, RANKL and TRAIL, in rheumatoid arthritis. *Sci Rep*. 2016;6(1):29713.
68. Wang P, Li S, Liu LN, Lv TT, Li XM, Li XP, et al. Circulating osteoprotegerin levels are elevated in rheumatoid arthritis: a systematic review and meta-analysis. *Clin Rheumatol*. 2017;36(10):2193–200.
69. Jhonson, A, Roberts, L, elkins G. complementary and alternative medicine for menopause. *Journal of evidence-based integrative medicine*. 2019. 1-14
70. Direktorat jendral bina gizi dan Kesehatan. Pedoman pencegahan dan penanggulangan kegemukan dan obesitas. Pencegahan dan Pengendalian Penyakit Tidak Menular. Kementerian Kesehatan RI. 2020. Hal 40
71. Giannakopoulos A, Efthymiadou A, Kritikou D, Chrysis D. Osteoprotegerin in infection-induced acute inflammatory states. *Heliyon*. 2024;10(6).
72. Suarjana I.N, Hamijoyo L, Suntoko B, Kasjmir Y.I, Handono K, Wijaya L.K. Lupus eritematosus dan sindrom antibodi antifosfolipid. dalam: Setiati S, Alwi I, Sudoyo A, Simadibrata M, Setyohadi B, Syam A, ed. Buku ajar ilmu penyakit dalam Jilid III Edisi VI. Jakarta: Interna Publishing: 2015; 3331-77.
73. Ariestine, D A, Kedokteran F, Sumatera Utara U. Hubungan Kadar Interleukin-6 dengan Aktivitas Penyakit. 2018
74. Hidayat R, Isbagio H, Setyohadi B, Setiati S. Correlation between receptor activator of nuclear factor- $\kappa\beta$ ligand (RANKL), and osteoprotegerin (OPG) with cartilage degradation in rheumatoid arthritis patients. *Acta Med Indones*. 2014 Jan;46:24–9.
75. Mudjaddid E, Puspitasari M, Setyohadi B, Dewiasty E. Hubungan Derajat Aktivitas Penyakit dengan Depresi pada Pasien Artritis Reumatoid. *J Penyakit Dalam Indones*. 2017;4(4):194
76. Boman A, Kokkonen H, Ärlestig L, Berglin E, Rantapää-Dahlqvist S. Receptor activator of nuclear factor kappa-B ligand (RANKL) but not sclerostin or gene

- polymorphisms is related to joint destruction in early rheumatoid arthritis. *Clin Rheumatol*. 2017;36:1005–12.
77. Akil N, Isbagio H, Sumariyono S. Correlation of Serum Level of Interleukin-6 and Disease Activity with Bone-resorption Activity in Premenopausal Rheumatoid Arthritis Patients. *Indones J Rheumatol*. 2013;4(1):231043
 78. Fadda S, Hamdy A, Abulkhair E, Mahmoud Elsify H, Mostafa A. Serum levels of osteoprotegerin and RANKL in patients with rheumatoid arthritis and their relation to bone mineral density and disease activity. *Egypt Rheumatol*. 2015;37:1–6.
 79. Widiyanto T, Hidayat R, Wibowo RMSAK, Shatri H. Correlation between anti-mutated citrullinated vimentin and bone turnover markers (CTX-1 and P1NP) in patients with rheumatoid arthritis in remission and low-disease activity. *Reumatologia*. 2022;60:252–7.
 80. Venetsanopoulou AI, Alamanos Y, Voulgari P V., Drosos AA. Epidemiology and Risk Factors for Rheumatoid Arthritis Development. *Mediterr J Rheumatol*. 2023 Dec;34:404.
 81. Boers M. Viewpoint: Glucocorticoids in the treatment of rheumatoid arthritis: Points to (re)consider. *Rheumatol (United Kingdom)*. 2023;62:3534–7.
 82. Hua C, Buttgerit F, Combe B. Glucocorticoids in rheumatoid arthritis: Current status and future studies. *RMD Open*. 2020;6:1–9.
 83. Hadwen B, Stranges S, Pope JE, Bartlett S, Boire G, Bessette L, et al. Risk factors for prevalent and incident hypertension in rheumatoid arthritis: data from the Canadian Early Arthritis Cohort. *Rheumatol Adv Pract*. 2024;8.
 84. Batko B, Urbański K, Świerkot J, Wiland P, Raciborski F, Jędrzejewski M, et al. Comorbidity burden and clinical characteristics of patients with difficult-to-control rheumatoid arthritis. *Clin Rheumatol*. 2019;38:2473–81.
 85. Taylor PC, Atzeni F, Balsa A, Gossec L, Müller-Ladner U, Pope J. The key comorbidities in patients with rheumatoid arthritis: A narrative review. *J Clin Med*. 2021;10:1–28.
 86. Tidblad L, Westerlind H, Delcoigne B, Askling J, Saevarsdottir S. Comorbidities and treatment patterns in early rheumatoid arthritis: A nationwide Swedish study. *RMD Open*. 2022;8:1–11.

87. Quaresma TO, de Almeida SCL, da Silva TA, Louzada-Júnior P, de Oliveira RDR. Comparative study of the synovial levels of RANKL and OPG in rheumatoid arthritis, spondyloarthritis and osteoarthritis. *Adv Rheumatol.* 2023;63.
88. Feng X, Xu X, Shi Y, Liu X, Liu H, Hou H, et al. Body Mass Index and the Risk of Rheumatoid Arthritis: An Updated Dose-Response Meta-Analysis. *Biomed Res Int.* 2019;2019.
89. Iqbal SM, Burns L, Grisanti J. Effect of Body Mass Index on the Disease Activity of Patients With Rheumatoid Arthritis in a Gender-Specific Manner and the Association of Respective Serum C-Reactive Protein Levels With the Body's Inflammatory Status. *Cureus.* 2020;12:1–10.
90. Oweis AO, Alawneh KM, Alshelleh SA, Alnaimat F, Alawneh D, Zahran DJ. Renal dysfunction among rheumatoid arthritis patients: A retrospective cohort study. *Ann Med Surg.* 2020;60:280–4.
91. Yoshimura Y, Yamanouchi M, Mizuno H, Ikuma D, Koizumi R, Kurihara S, et al. Efficacy and safety of first-line biological DMARDs in rheumatoid arthritis patients with chronic kidney disease. *Ann Rheum Dis.* 2024;1–10.
92. Nakashima A, Horita S, Matsunaga T, Inoue R, Zoshima T, Mizushima I, et al. Factors contributing to discrepant estimated glomerular filtration values measured by creatinine and cystatin C in patients with rheumatoid arthritis. *Sci Rep.* 2021;11:1–8.
93. Giles JT, Simon LS, Pope J, Paik JS, Grabner M, Quebe A, et al. Prevalence of Renal Impairment in a US Commercially Insured Rheumatoid Arthritis Population: A Retrospective Analysis. *Rheumatol Ther.* 2021;8:1383–91.
94. Wu C, Hu Y, Schafer P, Connolly SE, Wong R, Nielsen SH, et al. Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naïve, anticitrullinated protein antibody-positive patients with early rheumatoid arthritis. *RMD Open.* 2022;8:1–12.
95. Nava-Valdivia CA, Ponce-Guarneros JM, Saldaña-Cruz AM, Corona-Sanchez EG, Ramirez-Villafañã M, Perez-Guerrero EE, et al. Assessment of Serum sRANKL, sRANKL/OPG Ratio, and Other Bone Turnover Markers with the

- Estimated 10-Year Risk of Major and Hip Osteoporotic Fractures in Rheumatoid Arthritis: A Cross-Sectional Study. *Biomed Res Int.* 2021;2021.
96. Laurindo LF, de Maio MC, Barbalho SM, Guiguer EL, Araújo AC, de Alvares Goulart R, et al. Organokines in Rheumatoid Arthritis: A Critical Review. *Int J Mol Sci.* 2022;23.
97. Han S, Kim NR, Kang JW, Eun JS, Kang YM. Radial BMD and serum CTX- I can predict the progression of carotid plaque in rheumatoid arthritis: a 3-year prospective cohort study. *Arthritis Res Ther.* 2021;23:1–10.
98. Lim MJ, Jung KH, Kwon SR, Park W. Inflammation is responsible for systemic bone loss in patients with seropositive rheumatoid arthritis treated with rituximab. *Korean J Intern Med.* 2023;38:912–22.
99. Sakthiswary R, Uma Veshaliini R, Chin KY, Das S, Sirasanagandla SR. Pathomechanisms of bone loss in rheumatoid arthritis. *Front Med.* 2022;9.
100. Jura-Półtorak A, Szeremeta A, Olczyk K, Zoń-Giebel A, Komosińska-Vassey K. Bone metabolism and RANKL/OPG ratio in rheumatoid arthritis women treated with TNF- α inhibitors. Vol. 10, *Journal of Clinical Medicine.* 2021.

